A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- AbbVie
- Study ID
- NCT03178487
- Phase
- PHASE2
- Status
- Completed
Conditions
- Ankylosing Spondylitis (AS)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Upadacitinib — DRUGTablet
- Placebo — DRUGTablet
Study Details
The purpose of this study is to evaluate the safety and efficacy of upadacitinib in participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) or intolerance to or a contraindication for NSAIDs, and who are naïve to biologic disease-modifying anti-rheumatic drugs (bDMARD).
Key Dates
- Start date
- Oct 24, 2017
- Status verified
- Feb 2023
- Primary completion
- Jan 21, 2019
- Completion
- Feb 17, 2022
Study Design
- Enrollment
- 187 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Upadacitinib 15 mgParticipants will receive 15 mg upadacitinib orally once a day for 14 weeks in Period 1 and continue to receive 15 mg upadacitinib orally once a day for an additional 90 weeks in Period 2.
- Placebo Comparator: PlaceboParticipants will receive matching placebo orally once a day for 14 weeks in Period 1. In Period 2 participants will receive 15 mg upadacitinib orally once a day for 90 weeks.
Primary Outcome Measure
Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 14 [ Time Frame: Baseline and Week 14 ]
Locations (22)
Find similar trials in Phoenix, AZ
Related Studies
- Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation ResearchRecruiting · Brain Inflammation Collaborative · Delafield, Wisconsin